메뉴 건너뛰기
Blood
Volumn 126, Issue 25, 2015, Pages 2656-2657
Idelalisib has CLL on the run!
Author keywords

[No Author keywords available]
Indexed keywords

IDELALISIB; RITUXIMAB; ANTINEOPLASTIC AGENT;
EID: 84951334863     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-676890     Document Type: Note
Times cited : (4)
References (10)
  • 1
    • 84951268355 scopus 로고    scopus 로고
    • A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
    • O'Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015; 126(25):2686-2694.
    • (2015) Blood , vol.126 , Issue.25 , pp. 2686-2694
    • O'Brien, S.M.1    Lamanna, N.2    Kipps, T.J.3
  • 2
    • 84924378555 scopus 로고    scopus 로고
    • Second interim analysis of a phase 3 study of idelalisib (ZYDELIG-) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): Efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract]
    • Abstract 330
    • Sharman JP, Coutre SE, Furman RR, et al. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG-) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract]. Blood. 2014;124(21). Abstract 330.
    • (2014) Blood , vol.124 , Issue.21
    • Sharman, J.P.1    Coutre, S.E.2    Furman, R.R.3
  • 3
    • 84937023635 scopus 로고    scopus 로고
    • Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study
    • Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29(7): 1602-1604.
    • (2015) Leukemia , vol.29 , Issue.7 , pp. 1602-1604
    • Goede, V.1    Fischer, K.2    Engelke, A.3
  • 4
    • 84927732048 scopus 로고    scopus 로고
    • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
    • Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16): 2497-2506.
    • (2015) Blood , vol.125 , Issue.16 , pp. 2497-2506
    • Byrd, J.C.1    Furman, R.R.2    Coutre, S.E.3
  • 5
    • 84978375461 scopus 로고    scopus 로고
    • Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials [abstract]
    • Abstract e18030
    • Coutre S, Barrientos J, Brown JR, et al. Safety of idelalisib in B-cell malignancies: integrated analysis of eight clinical trials [abstract]. ASCO Meeting Abstracts. 2015;33(suppl). Abstract e18030.
    • (2015) ASCO Meeting Abstracts , vol.33
    • Coutre, S.1    Barrientos, J.2    Brown, J.R.3
  • 6
    • 84941200862 scopus 로고    scopus 로고
    • Management of adverse events associated with idelalisib treatment: Expert panel opinion
    • Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015:1-8.
    • (2015) Leuk Lymphoma , pp. 1-8
    • Coutré, S.E.1    Barrientos, J.C.2    Brown, J.R.3
  • 7
    • 84948718203 scopus 로고    scopus 로고
    • Idelalisib-associated enterocolitis: Clinicopathologic features and distinction from other enterocolitides
    • Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA. Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol. 2015; 39(12):1653-1660.
    • (2015) Am J Surg Pathol , vol.39 , Issue.12 , pp. 1653-1660
    • Louie, C.Y.1    DiMaio, M.A.2    Matsukuma, K.E.3    Coutre, S.E.4    Berry, G.J.5    Longacre, T.A.6
  • 8
    • 84948715031 scopus 로고    scopus 로고
    • Idelalisibassociated colitis: Histologic findings in 14 patients
    • Weidner AS, Panarelli NC, Geyer JT, et al. Idelalisibassociated colitis: histologic findings in 14 patients. Am J Surg Pathol. 2015;39(12):1661-1667.
    • (2015) Am J Surg Pathol , vol.39 , Issue.12 , pp. 1661-1667
    • Weidner, A.S.1    Panarelli, N.C.2    Geyer, J.T.3
  • 9
    • 33750807672 scopus 로고    scopus 로고
    • Cutting edge: The phosphoinositide 3-kinase p110 delta is critical for the function of CD41CD251 Foxp31 regulatory T cells
    • Patton DT, Garden OA, Pearce WP, et al. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD41CD251 Foxp31 regulatory T cells. J Immunol. 2006;177(10): 6598-6602.
    • (2006) J Immunol , vol.177 , Issue.10 , pp. 6598-6602
    • Patton, D.T.1    Garden, O.A.2    Pearce, W.P.3
  • 10
    • 84899659467 scopus 로고    scopus 로고
    • FOXP3 and scurfy: How it all began
    • Ramsdell F, Ziegler SF. FOXP3 and scurfy: how it all began. Nat Rev Immunol. 2014;14(5):343-349.
    • (2014) Nat Rev Immunol , vol.14 , Issue.5 , pp. 343-349
    • Ramsdell, F.1    Ziegler, S.F.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.